AI Article Synopsis
- Neoadjuvant therapy, including immunotherapy like toripalimab, is becoming a key treatment approach for muscle-invasive bladder cancer before surgery.
- A 57-year-old man diagnosed with muscle-invasive urothelial carcinoma was treated with toripalimab and gemcitabine, showing a partial response before undergoing radical cystectomy.
- The combination of toripalimab and gemcitabine demonstrates effective antitumor activity and may represent a promising new therapy for this type of cancer.
Article Abstract
Rationale: Routine neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma prior to radical surgery is curative. With the increase in cancer immunotherapy, neoadjuvant immunotherapy has been used as an important complement to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Toripalimab is a recombinant, humanized IgG4 monoclonal antibody directed against programmed cell death protein 1 and received the first global approval for the treatment of unresectable or metastatic melanoma in China on December 17, 2018.
Patient Concerns And Diagnosis: A 57-year-old man was admitted to our hospital because of hematuria for 1 week. The patient was diagnosed pathologically with muscle-invasive bladder urothelial carcinoma.
Interventions And Outcomes: The patient received neoadjuvant toripalimab combined with gemcitabine therapy. The patient showed partial response. Subsequently, radical cystectomy was performed.
Lessons: Toripalimab combined with gemcitabine exhibited accurate antitumor activity and may be a promising novel neoadjuvant therapy for muscle-invasive urothelial carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757928 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000028591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!